GlassScriptPhysician profile
Juan M Young
NPI 1942493796
$5,658.39
in general payments reported to CMS, 2019-2025
30 companies · $1,464 in 2025
The $1,464 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $437 · 2021: $533 · 2022: $706 · 2023: $1,021 · 2024: $798 · 2025: $1,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,179 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,179.13 |
| Education | $104.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,019.43 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $735.61 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $648.62 | 2019-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $389.49 | 2022-2025 | |
| Celgene Corporation | $286.52 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $256.02 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $183.96 | 2023-2025 | |
| Medtronic, INC. | $171.66 | 2022 | |
| Celltrion USA INC. | $150.48 | 2024-2025 | Vegzelma, Zymfentra |
| Ferring Pharmaceuticals INC. | $128.98 | 2022-2025 | Rebyota |
| Gilead Sciences, INC. | $125.19 | 2019-2024 | |
| Ambu INC. | $108.65 | 2022 | |
| Intercept Pharmaceuticals, INC. | $82.33 | 2020-2023 | Ocaliva |
| Aimmune Therapeutics, INC. | $40.07 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $39.85 | 2024-2025 | Voquezna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $35.62 | 2023-2024 | Kcentra |
| Ironwood Pharmaceuticals, INC | $31.57 | 2019-2020 | |
| Lilly USA, LLC | $24.25 | 2023 | |
| Shire North American Group INC | $24.01 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.10 | 2025 | Dupixent |
| Lumendi LLC | $21.31 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $20.33 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $19.92 | 2019 | |
| Vivus LLC | $18.45 | 2019 | |
| Ardelyx, INC. | $14.19 | 2023 | Ibsrela |
| Redhill Biopharma INC. | $13.60 | 2022 | |
| Ethicon US, LLC | $13.01 | 2019 | |
| Braintree Laboratories, INC. | $12.97 | 2019 | |
| Ucb, INC. | $12.24 | 2019 | |
| Alcresta Therapeutics, INC. | $6.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.